Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Total Enrollment
9000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2015-08-31
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This prospective non-intervention cohort study will enroll women in the first or early second trimester of pregnancy and follow them through delivery (or end of pregnancy) and 1 year postpartum.
Infants will also be followed until 1 year postpartum. Detailed medical and obstetrical information will be collected, as well as biological samples, in order to better elucidate the biological mechanisms leading to preterm delivery among Zambian women, in an effort to identify new strategies for prevention.
Infants will also be followed until 1 year postpartum. Detailed medical and obstetrical information will be collected, as well as biological samples, in order to better elucidate the biological mechanisms leading to preterm delivery among Zambian women, in an effort to identify new strategies for prevention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protein and Ultrasound Indicators of Preterm Birth
NCT01412931
Preterm Birth
COMPLETED
Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe
NCT00488462
Hypovolemic Shock
Hemorrhage
COMPLETED
NA
Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester
NCT02990767
Pre-Eclampsia
UNKNOWN
Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)
NCT03530332
Preterm Birth
TERMINATED
NA
Maternal Serum Markers Predicting Preeclampsia At Early Gestations
NCT05131282
Pre-eclampsia
Preterm Birth
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After consenting to study participation, women will be asked their detailed medical and obstetrical history. Participants will be provided standard of care. Blood, urine, and vaginal specimens will also be collected for the biorepository from those who consent to participate. Participants will also be screened for depression using the Edinburgh Postnatal Depression Scale (EPDS).
Throughout the study, participants will receive education about nutrition, pregnancy health, and the signs and symptoms of complications of pregnancy, including preterm labor and preterm premature rupture of membranes. Study visits for will be scheduled at 24, 28, 32, and 36 weeks gestation, at the time of discharge from the labor and delivery ward if possible, and at 7 days, 28 days, 42 days, 6 months, and 12 months postpartum
During each study visit (i.e., at 24, 32, and 36 weeks gestation), participants will receive the routinely recommended screening and treatment. This will consist of weight, blood pressure, and symptom screening, as well as measurements of fetal growth (fundal height) and fetal well being (fetal heart rate) at each visit. Screening and treatment of common pregnancy complications will also be provided if clinically indicated. All participants will undergo maternal hemoglobin testing and urinalysis at the 24 and 32-week visits. Maternal random fasting glucose testing will be conducted at the 28-week visit to screen for gestational diabetes. Syphilis titers will be obtained at a minimum at the 36 week visit for participants seropositive at screening to monitor serologic response after treatment. HIV testing will be repeated at 28 weeks for participants uninfected at screening, and HIV Viral Load and T cell assays will be performed at the 28- and 36-week visits for any seroconverters. Participants who are HIV-infected at screening will undergo HIV Viral Load and T cell assays at 28 and 36 weeks. At 24, 28, and 36 weeks, blood, urine, oropharyngeal, and vaginal swabs will be collected. We will also collect a rectal swab at the 36-week visit. .
At the time of delivery, the study team will obtain detailed information about the clinical management of the participant's delivery, as well as the delivery outcome for both the mother and her infant(s). A urinalysis, complete blood count with differential, blood chemistry testing will be performed. We will also obtain information on interval complications and mortality. In addition, we will collect samples of the placenta, umbilical cord, and cord blood after delivery for various assessments. 4-5 drops of cord blood will be applied to designated filter paper within pre-printed circles. Newborn heel-prick samples will be collected 24-72 hours after birth or sooner if the newborn is discharged from hospital within 24 hours of delivery.
There will be four study visits during the postnatal period, at 7 days, 42 days, 6 months, and 12 months postpartum. At these visits, we will assess interval maternal or infant complications and/or mortality and measure anthropometrics. Once again, participants will receive routinely recommended screening and treatment.
Maternal hemoglobin will be measured at all post-partum visits. Urinalysis will be performed at the 42-day visit only. Maternal blood, urine, oral/pharyngeal and vaginal specimens will be collected for storage and protocol related testing at the 42-day visit. Maternal syphilis and HIV testing will be repeated at the 42-day, 6- and 12-month visits for participants who are uninfected. HIV-exposed infants will have blood collected for early infant diagnosis at the 42-day and 6- and 12-month visits; this will be done via heel prick and dried blood spot (DBS) cards requiring five drops of blood. Maternal participants will again be screened for depression using the EPDS
Throughout the study, participants will receive education about nutrition, pregnancy health, and the signs and symptoms of complications of pregnancy, including preterm labor and preterm premature rupture of membranes. Study visits for will be scheduled at 24, 28, 32, and 36 weeks gestation, at the time of discharge from the labor and delivery ward if possible, and at 7 days, 28 days, 42 days, 6 months, and 12 months postpartum
During each study visit (i.e., at 24, 32, and 36 weeks gestation), participants will receive the routinely recommended screening and treatment. This will consist of weight, blood pressure, and symptom screening, as well as measurements of fetal growth (fundal height) and fetal well being (fetal heart rate) at each visit. Screening and treatment of common pregnancy complications will also be provided if clinically indicated. All participants will undergo maternal hemoglobin testing and urinalysis at the 24 and 32-week visits. Maternal random fasting glucose testing will be conducted at the 28-week visit to screen for gestational diabetes. Syphilis titers will be obtained at a minimum at the 36 week visit for participants seropositive at screening to monitor serologic response after treatment. HIV testing will be repeated at 28 weeks for participants uninfected at screening, and HIV Viral Load and T cell assays will be performed at the 28- and 36-week visits for any seroconverters. Participants who are HIV-infected at screening will undergo HIV Viral Load and T cell assays at 28 and 36 weeks. At 24, 28, and 36 weeks, blood, urine, oropharyngeal, and vaginal swabs will be collected. We will also collect a rectal swab at the 36-week visit. .
At the time of delivery, the study team will obtain detailed information about the clinical management of the participant's delivery, as well as the delivery outcome for both the mother and her infant(s). A urinalysis, complete blood count with differential, blood chemistry testing will be performed. We will also obtain information on interval complications and mortality. In addition, we will collect samples of the placenta, umbilical cord, and cord blood after delivery for various assessments. 4-5 drops of cord blood will be applied to designated filter paper within pre-printed circles. Newborn heel-prick samples will be collected 24-72 hours after birth or sooner if the newborn is discharged from hospital within 24 hours of delivery.
There will be four study visits during the postnatal period, at 7 days, 42 days, 6 months, and 12 months postpartum. At these visits, we will assess interval maternal or infant complications and/or mortality and measure anthropometrics. Once again, participants will receive routinely recommended screening and treatment.
Maternal hemoglobin will be measured at all post-partum visits. Urinalysis will be performed at the 42-day visit only. Maternal blood, urine, oral/pharyngeal and vaginal specimens will be collected for storage and protocol related testing at the 42-day visit. Maternal syphilis and HIV testing will be repeated at the 42-day, 6- and 12-month visits for participants who are uninfected. HIV-exposed infants will have blood collected for early infant diagnosis at the 42-day and 6- and 12-month visits; this will be done via heel prick and dried blood spot (DBS) cards requiring five drops of blood. Maternal participants will again be screened for depression using the EPDS
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pregnancy
Stillbirth
Preterm Birth
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Pregnant women ≥15 years will be eligible to participate. Additionally, participants will:
1. Have a completed screening ultrasound with gestational age \< 20 weeks
2. Be HIV-uninfected at enrollment (NB: prior to Protocol Version 4.0 \[3 Nov 2017\] enrolled both HIV-infected and uninfected women)
3. Have a singleton or twin pregnancy with fetal heart tones confirmed by ultrasound
4. Reside within Lusaka with no plans to relocate during the study follow-up period
5. Be willing to provide written, informed consent
6. Be willing to allow their infants to participate in the study
1. Have a completed screening ultrasound with gestational age \< 20 weeks
2. Be HIV-uninfected at enrollment (NB: prior to Protocol Version 4.0 \[3 Nov 2017\] enrolled both HIV-infected and uninfected women)
3. Have a singleton or twin pregnancy with fetal heart tones confirmed by ultrasound
4. Reside within Lusaka with no plans to relocate during the study follow-up period
5. Be willing to provide written, informed consent
6. Be willing to allow their infants to participate in the study
Exclusion Criteria
1. Pregnant women \> 24 weeks' gestation or with screening ultrasound ≥ 16 weeks
2. Infants born to women not enrolled in the study
2. Infants born to women not enrolled in the study
Minimum Eligible Age
15 Years
Maximum Eligible Age
49 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Global Alliance to Prevent Prematurity and Stillbirth
UNKNOWN
Sponsor Role
collaborator
Bill and Melinda Gates Foundation
OTHER
Sponsor Role
collaborator
University of North Carolina, Chapel Hill
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeff Stringer, MD
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kamwala Health Centre
Lusaka, , Zambia
Site Status
University Teaching Hospital
Lusaka, , Zambia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Zambia
References
Explore related publications, articles, or registry entries linked to this study.
Kim CJ, Romero R, Kusanovic JP, Yoo W, Dong Z, Topping V, Gotsch F, Yoon BH, Chi JG, Kim JS. The frequency, clinical significance, and pathological features of chronic chorioamnionitis: a lesion associated with spontaneous preterm birth. Mod Pathol. 2010 Jul;23(7):1000-11. doi: 10.1038/modpathol.2010.73. Epub 2010 Mar 26.
Reference Type
BACKGROUND
Myatt L, Eschenbach DA, Lye SJ, Mesiano S, Murtha AP, Williams SM, Pennell CE; International Preterm Birth Collaborative Pathways and Systems Biology Working Groups. A standardized template for clinical studies in preterm birth. Reprod Sci. 2012 May;19(5):474-82. doi: 10.1177/1933719111426602. Epub 2012 Feb 16.
Reference Type
BACKGROUND
Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. The preterm parturition syndrome. BJOG. 2006 Dec;113 Suppl 3(Suppl 3):17-42. doi: 10.1111/j.1471-0528.2006.01120.x.
Reference Type
BACKGROUND
Lawn JE, Kinney MV, Black RE, Pitt C, Cousens S, Kerber K, Corbett E, Moran AC, Morrissey CS, Oestergaard MZ. Newborn survival: a multi-country analysis of a decade of change. Health Policy Plan. 2012 Jul;27 Suppl 3:iii6-28. doi: 10.1093/heapol/czs053.
Reference Type
BACKGROUND
Nour NM. Premature delivery and the millennium development goal. Rev Obstet Gynecol. 2012;5(2):100-5.
Reference Type
BACKGROUND
Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics. 2004 Aug;114(2):372-6. doi: 10.1542/peds.114.2.372.
Reference Type
BACKGROUND
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012 Jun 9;379(9832):2162-72. doi: 10.1016/S0140-6736(12)60820-4.
Reference Type
BACKGROUND
March of Dimes P, Save the Children, WHO. Born Too Soon: The Global Action Report on Preterm Birth. In. Edited by Eds CP Howson MK, JE Lawn. Geneva: World Health Organization; 2012.
Reference Type
BACKGROUND
Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008 Jan 5;371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4.
Reference Type
BACKGROUND
Oliver RS, Lamont RF. Infection and antibiotics in the aetiology, prediction and prevention of preterm birth. J Obstet Gynaecol. 2013 Nov;33(8):768-75. doi: 10.3109/01443615.2013.842963.
Reference Type
BACKGROUND
Gotsch F, Gotsch F, Romero R, Erez O, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, Hassan S, Yeo L. The preterm parturition syndrome and its implications for understanding the biology, risk assessment, diagnosis, treatment and prevention of preterm birth. J Matern Fetal Neonatal Med. 2009;22 Suppl 2:5-23. doi: 10.1080/14767050902860690. No abstract available.
Reference Type
BACKGROUND
Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why? Lancet. 2005 Mar 5-11;365(9462):891-900. doi: 10.1016/S0140-6736(05)71048-5.
Reference Type
BACKGROUND
Iams JD. Clinical practice. Prevention of preterm parturition. N Engl J Med. 2014 Jan 16;370(3):254-61. doi: 10.1056/NEJMcp1103640. No abstract available.
Reference Type
BACKGROUND
Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med. 2010 Feb 11;362(6):529-35. doi: 10.1056/NEJMra0904308. No abstract available.
Reference Type
BACKGROUND
Romero R, Espinoza J, Gotsch F, Kusanovic JP, Friel LA, Erez O, Mazaki-Tovi S, Than NG, Hassan S, Tromp G. The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG. 2006 Dec;113 Suppl 3(Suppl 3):118-35. doi: 10.1111/j.1471-0528.2006.01150.x.
Reference Type
BACKGROUND
Liong S, Di Quinzio MK, Fleming G, Permezel M, Rice GE, Georgiou HM. Prediction of spontaneous preterm labour in at-risk pregnant women. Reproduction. 2013 Aug 21;146(4):335-45. doi: 10.1530/REP-13-0175. Print 2013 Oct.
Reference Type
BACKGROUND
Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987 Jun;150:782-6. doi: 10.1192/bjp.150.6.782.
Reference Type
BACKGROUND
Wisner KL, Parry BL, Piontek CM. Clinical practice. Postpartum depression. N Engl J Med. 2002 Jul 18;347(3):194-9. doi: 10.1056/NEJMcp011542. No abstract available.
Reference Type
BACKGROUND
Aleman A, Cafferata ML, Gibbons L, Althabe F, Ortiz J, Sandoval X, Padilla-Raygoza N, Belizan JM. Use of antenatal corticosteroids for preterm birth in Latin America: providers knowledge, attitudes and practices. Reprod Health. 2013 Jan 29;10:4. doi: 10.1186/1742-4755-10-4.
Reference Type
BACKGROUND
Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2000;(2):CD000065. doi: 10.1002/14651858.CD000065.
Reference Type
BACKGROUND
Appiagyei A, Vwalika B, Spelke MB, Conner MG, Mabula-Bwalya CM, Kasaro MP, Honart AW, Kumwenda A, Stringer EM, Stringer JSA, Price JT. Maternal mid-upper arm circumference to predict small for gestational age: Findings in a Zambian cohort. Int J Gynaecol Obstet. 2023 May;161(2):462-469. doi: 10.1002/ijgo.14517. Epub 2022 Oct 31.
Reference Type
DERIVED
Price JT, Vwalika B, Edwards JK, Cole SR, Kasaro MP, Rittenhouse KJ, Kumwenda A, Lubeya MK, Stringer JSA. Maternal HIV Infection and Spontaneous Versus Provider-Initiated Preterm Birth in an Urban Zambian Cohort. J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):860-868. doi: 10.1097/QAI.0000000000002654.
Reference Type
DERIVED
Rittenhouse KJ, Mwape H, Nelson JAE, Mwale J, Chipili G, Price JT, Hudgens M, Stringer EM, De Paris K, Vwalika B, Stringer JSA. Maternal HIV, antiretroviral timing, and spontaneous preterm birth in an urban Zambian cohort: the role of local and systemic inflammation. AIDS. 2021 Mar 15;35(4):555-565. doi: 10.1097/QAD.0000000000002808.
Reference Type
DERIVED
Rittenhouse KJ, Vwalika B, Keil A, Winston J, Stoner M, Price JT, Kapasa M, Mubambe M, Banda V, Muunga W, Stringer JSA. Improving preterm newborn identification in low-resource settings with machine learning. PLoS One. 2019 Feb 27;14(2):e0198919. doi: 10.1371/journal.pone.0198919. eCollection 2019.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.unc.edu
University of North Carolina website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-2113
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings
NCT01990625
COMPLETED
NA
Diagnostic Accuracy of a Novel Machine Learning Algorithm to Estimate Gestational Age
NCT05433519
COMPLETED
Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia
NCT04058405
COMPLETED
Mother Infant Nutrition Study
NCT04132310
ENROLLING_BY_INVITATION
Effects of Recurrent PE on Women and Offspring
NCT05134285
UNKNOWN
Mothers Working to Prevent Early Stillbirth Study 20-28
NCT06005272
RECRUITING
Angiogenic Factors in the Conservative Management of Gestational Hypertension
NCT06123377
RECRUITING
NA
Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women
NCT05534932
ACTIVE_NOT_RECRUITING
NA
Family Study on Preeclampsia
NCT00344162
COMPLETED
Proteomic Assessment of Preterm Birth
NCT01371019
COMPLETED
First-trimester Prediction of Preeclampsia
NCT02189148
COMPLETED
Saving Babies' Lives Project Impact and Results Evaluation: a Mixed Methodology Study
NCT03231007
COMPLETED
Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting
NCT02339077
COMPLETED
Pre-Eclampsia And Growth Restriction: a Longitudinal Study
NCT02379832
COMPLETED
Peripartum Anesthetic Management of Patients With Preeclampsia
NCT05237011
UNKNOWN
Predicting Late-onset Preeclampsia at 10-14 Weeks of Pregnancy
NCT04075708
COMPLETED
Prediction of Preeclampsia (PE) at 11-13 Week
NCT03554681
COMPLETED
Screening and Treating Asymptomatic Bacteriuria Every Trimester and Preterm Birth
NCT03274960
COMPLETED
NA
Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer
NCT05460416
RECRUITING
PHASE3
Ambulatory Blood Pressure and the Normal Increase in Maternal Blood Pressure Postpartum
NCT02912403
WITHDRAWN
Prospective Study of the Influence of Periodontal Diseases on Pre-term Birth: Observation in the Maternity Hospital of Nantes
NCT00982813
TERMINATED
NA
The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study
NCT06517628
RECRUITING
The Sweet PEA Study: Effects of Diet During Pregnancy on Infant Growth and Development.
NCT04674033
COMPLETED
Spontaneous Preterm Birth Marker Test
NCT03123926
UNKNOWN
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
NCT04766866
RECRUITING
NA